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The metabolic syndrome and uric acid nephrolithiasis: Novel
features of renal manifestation of insulin resistance.
Background. Uric acid nephrolithiasis primarily results from
low urinary pH, which increases the concentration of the in-
soluble undissociated uric acid, causing formation of both uric
acid and mixed uric acid/calcium oxalate stones. These patients
have recently been described as exhibiting features of insulin
resistance. This study was designed to evaluate if insulin resis-
tance is associated with excessively low urinary pH in overtly
healthy volunteers (non-stone formers) and if insulin resistance
may explain the excessively low urinary pH in patients with uric
acid nephrolithiasis.
Methods. Fifty-five healthy volunteers (non stone-formers)
with a large range of body mass index and 13 patients with re-
current uric acid nephrolithiasis underwent hyperinsulinemic
euglycemic clamp, 24-hour urinary studies, and anthropometric
measurements of adiposity. A subgroup of 35 non-stone form-
ers had 2-hour timed urinary collection before and during the
hyperinsulinemic phase of the clamp studies.
Results. For the non-stone former population, low insulin
sensitivity measured as glucose disposal rate significantly cor-
related with low 24-hour urinary pH (r = 0. 35; P = 0.01). In
addition to the previously described acidic urine pH and hy-
pouricosuria, patients with recurrent uric acid nephrolithiasis
were found to be severely insulin resistant (glucose disposal
rate: uric acid stone-formers vs. normals; 4.1 ± 1.3 vs. 6.9 ±
2.1 mg/min/kg of lean body mass, P = 0.008). Acute hyperin-
sulinemia was associated with higher urinary pH (6.1 ± 0.7 at
baseline to 6.8 ± 0.7 during hyperinsulinemia; P < 0.0001), uri-
nary ammonia excretion (2.7 ± 1.6 mEq/2 hr at baseline and
4.0 ± 2.6 mEq/2 hr P = 0.002) and urinary citrate excretion
(48 ± 33 mg/2 hr at baseline and 113 ± 68 mg/2 hr P <
0.0001).
Conclusion. We conclude that one renal manifestation of in-
sulin resistance may be low urinary ammonium and pH. This
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defect can result in increased risk of uric acid precipitation de-
spite normouricosuria.
An increasing percentage of our population is af-
fected by obesity and the metabolic syndrome, a con-
dition metabolically characterized by insulin resistance
and clinically defined by the clustering of abdominal obe-
sity, dyslipidemia, elevated blood pressure, and elevated
fasting plasma glucose [1–3]. We have recently reported
that patients with recurrent uric acid kidney stones man-
ifest clinical and metabolic abnormalities consistent with
the metabolic syndrome [4, 5]. Uric acid stone formers
typically have urinary pH <5.5. This results in increased
concentrations of the sparingly soluble undissociated uric
acid (pKa 5.5), which directly promotes formation of uric
acid stones [5–8]. Calcium oxalate stones can also de-
velop from uric acid–induced crystallization of calcium
salts [8–10]. The term “gouty diathesis” has been coined
to describe this empiric collection of findings [11, 12].
Because of the overlap of clinical features between gouty
diathesis and the metabolic syndrome [13], the question
arises whether defective biologic activity of insulin also
affects urinary acidification, the main pathophysiologic
abnormality of gouty diathesis. Little is known about the
physiologic role of insulin in the kidney beyond renal glu-
coneogenesis [14]. However, insulin has been shown to
be antinatriuretic [15–18], and stimulate renal Na+ trans-
port in vitro [19–20] and ammonium production from
L-glutamine in renal proximal tubules [21, 22]. It is there-
fore possible that impaired biologic activity of insulin in
insulin-resistant individuals extends beyond abnormali-
ties in peripheral glucose utilization to abnormalities in
urinary acidification. This study was designed to eval-
uate whether insulin resistance is associated with ex-
cessively low urinary pH in overtly healthy volunteers
(non-stone formers) and whether insulin resistance may
explain the excessively low urinary pH in patients with
uric acid nephrolithiasis.
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METHODS
Experimental subjects
A total of 55 non-stone former volunteers (33 males
and 22 females) with a wide range of adiposity (body fat
between 6% and 47% of body weight) were included in
this study. An additional group of 13 patients (11 males
and 2 females) with diagnosis of uric acid urolithiasis
was enrolled from the stone clinic at the Center of Min-
eral Metabolism and Clinical Research of the Univer-
sity of Texas Southwestern Medical Center. The ethnic
composition was: 47 Caucasians, 17 Asian Indians, 2 His-
panics, and 2 African Americans). Subjects with chronic
diarrhea, impaired renal function (creatinine clearance
less than 60 mL/min), urinary tract infection, liver dis-
ease, and cardiovascular disease, and those on convert-
ing enzyme inhibitors, angiotensin receptor blockers, or
b-blockers were excluded. Subjects who were receiving
lipid-altering drugs, who had abnormal thyroid function
tests or proteinuria, or were participating in strenuous
physical exercise programs were also excluded from the
study. The stone-formers were instructed to discontinue
all medications or treatment for renal stones (thiazide, al-
kali therapy) 1 month prior to entering the study. No one
received drugs that could affect urate metabolism (such as
allopurinol or a high dose acetyl-salicylate). None were
receiving oral hypoglycemic agents and/or insulin. The
stone-forming patients were identified by records of stone
analysis. The University of Texas Southwestern Institu-
tional Review Board Committee approved the study and
informed consent was obtained from each of the partici-
pating subjects.
Study protocol
The study comprised an outpatient evaluation and
a stabilization phase, during which each participating
subject was maintained on an isocaloric diet (30% fat,
55% carbohydrate, 15% protein, and 300 mg cholesterol,
400 mg calcium, 800 mg phosphorus, 100 mEq sodium,
40 mEq potassium) with a fixed acid ash content and suf-
ficient fluid (distilled water) to ensure 2 liters of urine per
day. After 2 days of stabilization, subjects were admit-
ted in the General Clinical Research Center (GCRC) for
3 days (study days 3, 4, and 5) and maintained on a
constant metabolic diet of the above composition. Dur-
ing study days 3 and 4, 24-hour urine was collected un-
der mineral oil and refrigerated. Urine samples were
later analyzed for total volume, pH, creatinine, sodium,
potassium, chloride, uric acid, citrate, sulfate, ammonium,
titratable acidity, and bicarbonate/CO2. On the morning
of study day 5, breakfast was withheld, and euglycemic
hyperinsulinemic clamp procedure was performed af-
ter an overnight fast. Two polyethylene catheters were
placed under local anesthesia. One catheter was placed
in a dorsal hand vein for blood sampling and the hand
was kept in a heat box at 70◦C for arterialization of ve-
nous blood. An arterialized venous blood sample was ob-
tained for determination of pH, blood gases, and lipid
profile at 0800, 1000, and 1200 hours. At 0800, a primed-
continuous infusion of regular insulin (Humulin, Squibb-
Novo, Princeton, NJ, USA) was started at a rate of 80 mU/
m2 (body surface area)/min, and was continued for
2 hours (until 1000 hours). The insulin infusion rate of
80 mU/m2/min was expected to assure complete suppres-
sion of the hepatic glucose output during the hyperin-
sulinemic phase of study. A 20% glucose infusion was
started after 4 minutes of insulin infusion at the rate cal-
culated to maintain plasma glucose concentration at the
fasting levels throughout the clamp procedure, according
to the method of DeFronzo et al [23]. Blood for plasma
glucose concentration measurements was drawn every
5 minutes for the entire duration of the study. The rate of
glucose infusion was calculated based on glucose concen-
tration obtained at various times during the clamp study.
Mean plasma glucose concentrations were 88 ± 9 and
96 ± 13 mg/dL in the non-stone formers group and in the
uric acid nephrolithiasis group, respectively, during the
last 40 minutes of the study. Blood for the determination
of insulin levels was drawn every 10 minutes from −30 to
0 minutes (baseline phase) and from 80 to 120 minutes
(hyperinsulinemic phase, following 80 minutes of equili-
bration time). Mean plasma insulin concentrations were
180 ± 46 and 172 ± 29 lU/mL in the non-stone formers
and in the uric acid nephrolithiasis patients, respectively,
during the last 40 minutes of the study. In a subgroup of
35 non-stone formers (22 males and 13 females) we also
obtained 2-hour urine from 0600 to 0800 before initiation
of insulin infusion. Urine was collected under mineral oil
for evaluation of total volume, pH, creatinine, citrate, and
ammonium. At the end of the hyperinsulinemic clamp
(2 hours’ duration) we again collected 2-hour urine for
analysis.
All participants had anthropometric measurements
during hospitalization at the GCRC. Height and weight
were measured by standard procedures. Waist circum-
ference was measured using a flexible measuring tape
with a tension caliper at the extremity (Gulick-Creative
Health Product, Inc., Plymouth, MI, USA), midway be-
tween xyphoid and umbilicus during the mid-expiratory
phase. Body composition was determined using under-
water weighing, as previously reported [24].
Analytic procedures and calculations
Serum sodium, potassium, chloride, and total carbon
dioxide, calcium, phosphorus, uric acid, BUN, creati-
nine, cholesterol, and triglyceride concentrations were
obtained as a part of chem-24 (GCRC Core Laboratory
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using Beckman CX9ALX; Beckman Coulter, Inc.,
Fullerton, CA, USA). Serum very low-density
lipoprotein-cholesterol (VLDL-C), low-density
lipoprotein-cholesterol (LDL-C), and high-density
lipoprotein-cholesterol (HDL-C) concentrations were
measured at the Center for Human Nutrition at the In-
vestigator’s Laboratory. Plasma glucose was determined
by the glucose oxidase method using a Beckman glucose
analyzer (Beckman Coulter, Inc.). Plasma insulin was
determined by immunoassay at Linco Research, Inc.
(St. Louis, MO, USA). Urinary sodium and potassium
were measured by flame photometry. Urinary chloride
was measured calorimetrically by silver precipitation.
Urinary uric acid was analyzed by the uricase method
and creatinine by the picric acid method. Urinary pH
was measured with a pH electrode. Urinary citrate
was determined enzymatically using reagents from
Boehringer-Mannheim Biochemicals (Indianapolis, IN,
USA). Urinary ammonium was determined by the
glutamate dehydrogenase method. Urinary sulfate was
determined by ion chromatography. Urinary titratable
acidity was measured directly using automated burette
end point titration system (Radiometer, Copenhagen,
Denmark). The milliequivalents of OH− required titrat-
ing the urinary pH to 7.4 yielded titratable acidity (TA).
Net acid excretion (NAE) was calculated as (NH+4 +
TA) − (HCO−3 + ionized citrate), all expressed in
milliequivalents. Urinary HCO3− was calculated from
urinary pH and pCO2, and milliequivalents of ionized
citrate was calculated from urinary pH and a pKa of
citrate 2-/citrate 3- of 5.6. Arterialized venous blood
and urinary pH and blood and urinary carbon diox-
ide were determined aerobically at 37◦C Radiometer
BMS-3 pH electrode (Copenhagen, Denmark) and
Servinghaus electrode. The arterialized venous plasma
bicarbonate concentration was calculated from blood pH
and pCO2 (Henderson-Hasselbach equation). Glucose
disposal rate during the hyperinsulinemic phase was
calculated from the infusion rate of glucose during each
10-minute interval from time 80 to 120 minutes. Urinary
glucose loss was accounted for in the calculation of
glucose disposal rates as an estimate of insulin sensitivity
in the study subjects.
Statistical analysis
Student t test was used for comparison of study groups.
Spearman correlation coefficients were used to assess the
association between continuous variables. Paired t test
was used to compare means of urinary variables at base-
line and during hyperinsulinemic phase of the clamps. Re-
sults are presented as mean ± standard deviation (SD).
Statistical analysis was performed with SAS 8.0 (SAS In-
stitute, Cary, NC, USA).
Table 1. General and metabolic characteristics of non-stone formers
and uric acid nephrolithiasis patients
Uric acid
Non-stone nephrolithiasis
formers patients P value
N (male/female) 55 (33/22) 13 (11/2) –
Age years 31 ± 11 53 ± 10 <0.0001
BMI kg/m2 24 ± 4 31 ± 4 <0.0001
Body fat % of body weight 23 ± 10 36 ± 7 <0.0001
Waist circumference cm 83 ± 13 105 ± 11 <0.0001
Systolic blood pressure 116 ± 19 138 ± 11 0.0002
mm Hg
Diastolic blood pressure 73 ± 10 86 ± 10 0.0002
mm Hg
Total plasma cholesterol 160 ± 32 201 ± 30 0.0007
mg/dL
Plasma triglycerides mg/dL 99 ± 69 200 ± 81 0.002
LDL-cholesterol mg/dL 97 ± 27 128 ± 27 0.002
HDL-cholesterol mg/dL 45 ± 10 34 ± 10 0.004
Fasting glucose mg/dL 87 ± 9 101 ± 15 <0.0001
Fasting insulin U/mL 13 ± 9 13 ± 7 0.9
Glucose disposal rate 9.0 ± 2.5 6.3 ± 2.4 0.008
mg/min/kg of lean body mass
Results are expressed as mean ± SD. P values are derived from Student t test.
RESULTS
Table 1 is a summary of the general and metabolic
characteristics of the study population, which included 55
subjects with no history of kidney stones and 13 subjects
with history of uric acid nephrolithiasis. The ethnic com-
position was 47 Caucasians (originating from Europe),
17 Asian Indians (originating from the Indian Subcon-
tinent), 2 Hispanics (originating from Latin America),
and 2 African Americans. None of the subjects with uric
acid nephrolithiasis had a history of diabetes. Two pa-
tients were found to have elevated fasting glucose, and
one patient was diagnosed with diabetes at the time of
entry into the study. As expected, the patients with uric
acid nephrolithiasis had general features of the metabolic
syndrome, including increased body fat content, waist
circumference, blood pressure, serum triglycerides, and
low serum HDL-cholesterol concentrations. Glucose dis-
posal rate during hyperinsulimemia was also significantly
lower in the patients with uric acid nephrolithiasis. The
results on serum and urinary chemistries are summa-
rized in Tables 2 and 3, respectively. The main biochem-
ical changes found in serum of uric acid stone-forming
patients were slightly higher concentrations of sodium,
potassium, and uric acid (Table 2). Uric acid stone-
formers had lower urinary pH and citrate, and higher
titratable acid and net acid excretion (Table 3). Although
urinary ammonium was not significantly lower, the frac-
tion of net acid excretion composed of ammonium was
significantly decreased in uric acid stone-formers, indicat-
ing that more protons are excreted with non-NH3 buffers.
To evaluate the relationship between insulin resistance
and urinary acidification we first analyzed the correlation
between glucose disposal rate during hyperinsulinemic
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Table 2. Serum chemistries in non-stone formers and in uric acid
nephrolithiasis patients
Uric acid
Non-stone nephrolithiasis
formers patients P value
Na mEq/L 138 ± 6 144 ± 11 0.005
K mEq/L 4.0 ± 0.3 4.3 ± 0.4 0.008
Cl mEq/L 105 ± 2 10.5 ± 3 0.9
CO2 mEq/L 26 ± 2 23 ± 3.0 0.1
BUN mg/dL 12 ± 3 13 ± 2.0 0.1
Cr mg/dL 0.9 ± 0.2 1.0 ± 0.2 0.3
Ca mg/dL 9.0 ± 0.4 8.9 ± 0.60 4
P mg/dL 3.0 ± 0.4 3.0 ± 0.4 0.7
Uric acid mg/dL 5.8 ± 1.3 7.6 ± 1.4 <0.0001
pH 7.40 ± 0.02 7.42 ± 0.02 0.02
pCO2 mm Hg 42.3 ± 3.8 40.5 ± 2.7 0.1
HCO3− mEq/L 25.7 ± 1.8 25.7 ± 1.2 0.9
Results are expressed as mean ± SD. P values are derived from Student t test.
Table 3. Urinary chemistries and acid excretion in non-stone formers
and uric acid nephrolithiasis patients
Uric acid
Non-stone nephrolithiasis
formers patients P value
pH 6.2 ± 0.4 5.5 ± 0.2 <0.0001
NH+4 mEq/d 34 ± 11 33 ± 9 0.9
Citrate mg/d 638 ± 285 367 ± 184 0.002
Citrate mEq/d 7.5 ± 3.4 4.9 ± 2.4 0.01
Titratable acids mEq/d 23 ± 10 32 ± 8 0.002
Bicarbonate mEq/d 2.6 ± 4.0 0.34 ± 0.2 0.0001
NAE mEq/d 46 ± 20 60 ± 13 0.02
NH+4 /NAE 0.8 ± 0.3 0.55 ± 0.09 0.002
Total volume mL/d 2335 ± 851 2095 ± 500 0.3
Na mEq/d 103 ± 48 75 ± 29 0.05
K mEq/d 55 ± 21 31 ± 7 <0.0001
Cl mEq/d 100 ± 49 78 ± 23 0.1
Cr mg/d 1590 ± 420 1623 ± 515 0.8
SO4 mEq/d 11.4 ± 3.6 9.5 ± 2.5 0.07
Cr clearance mL/min 121 ± 41 123 ± 29 0.9
Results are expressed as mean ± SD. P values are derived from Student t test.
clamps and 24-hour urinary pH in the two study groups.
As shown in Figure 1, for non-stone formers, the rela-
tionship was significant with an r value of +0.35 (P =
0.01). Lower glucose disposal rate was associated with
lower urinary pH. The uric acid stone formers tended to
cluster in the area of more severe insulin resistance with
relatively lower variability in both glucose disposal rates
and urinary pH, as compared to the non-stone formers.
Likely as a consequence of the smaller sample size, the
smaller range of insulin sensitivity and urinary pH, no
significant relationship was found between insulin sensi-
tivity and urinary pH within the group of patients with
uric acid nephrolithiasis.
Factors such as age and body composition can con-
found the evaluation of the role of insulin resistance
on the excessive urinary acidity of patients with uric
acid nephrolithiasis. To minimize the effect of age and
body composition on insulin resistance differences be-
tween non-stone formers and nephrolithiasis patients, we
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Fig. 1. Relationship between glucose disposal rate during
hyperinsulinemic-euglycemic clamp and 24-hour urinary pH.
Open dots represent data from non-stone formers and closed dots
represent data from patients with uric acid nephrolithiasis. The r value
for the correlation was 0.35 (P = 0.01 Spearman correlation) within
the non-stone formers.
Table 4. General characteristics, urinary, and metabolic data in the
study subgroup selected for age above 40 years
Patients
Non-stone with uric acid
formers nephrolithiasis P value
N (male/female) 13 (6/7) 13 (11/2)
Age years 50 ± 6 53 ± 10 0.3
Body fat content % of total 28 ± 10 36 ± 7 0.06
body mass
Waist circumference cm 91 ± 19 105 ± 11 0.06
Glucose disposal rate mg/ 7.8 ± 2.1 6.3 ± 2.4 0.2
min/kg of lean body mass
Urinary pH 6.1 ± 0.5 5.5 ± 0.2 0.0003
Urinary NH4
+ mEq/d 37 ± 9 33 ± 9 0.3
Urinary NH4
+/NAE 0.92 ± 0.38 0.55 ± 0.09 0.002
Urinary citrate mg/d 698 ± 252 367 ± 184 0.001
Urinary citrate mEq/d 7.5 ± 3.3 4.9 ± 2.4 0.01
Urinary citrate/NAE 0.2 ± 0.2 0.08 ± 0.04 <0.0001
Results are expressed as mean ± SD. P values are derived from Student t test.
further analyzed selected subjects who were older than
40 years of age from the two study groups. As shown in
Table 4, these subgroups were more homogeneous and
more comparable in terms of body fat content, waist cir-
cumference, and glucose disposal rates. Despite the simi-
larities of metabolic and body composition variables, the
patients with uric acid nephrolithiasis still have signif-
icantly lower urinary pH when compared to this non-
stone formers subgroup. The differences in urinary pH
remained significant even after statistical adjustment for
age, total body fat content, and waist circumference
(P value = 0.046). Similar to what was found in the
comparison with the whole non-stone former group, this
young subgroup of uric acid nephrolithiasis patients had
decreased urinary citrate and decreased ratio of ammo-
nium to net acid excretion.
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Fig. 2. Urinary pH (A), urinary ammonium
(B), and urinary citrate (C) at baseline
and during the hyperinsulinemic phase of
the clamp studies. These studies were per-
formed in 2-hour timed urinary collection for
22 males and 13 females of the non-stone
formers group. Plasma insulin concentrations
were 14 ± 10 lU/mL at baseline and 173 ±
26 lU/mL during the last 40 minutes of
the clamp studies. Lines represent individual
changes. Means (•) are reported for each vari-
able at baseline and during hyperinsulinemia.
Mean and SD for urinary pH were 6.1 ± 0.7
and 6.8 ± 0.7. Mean and SD for urinary am-
monia were 2.7 ± 1.6 and 4.0 ± 2.6 mEq/2 hr.
Mean and SD for urinary citrate were 48 ±
33 and 113 ± 68 mg/2 hr. P values are derived
from paired t test.
If insulin resistance contributes to lower urinary pH,
ammonium, and citrate, one would expect an increase
in these parameters during hyperinsulinemia. Figure 2
depicts the changes in urinary variables at baseline
plasma insulin concentrations and during hyperinsuline-
mia. Thirty-five non-stone formers (22 males and 13 fe-
males) had 2-hour timed urinary collection before and
during hyperinsulinemic clamp. The ethnic composition
of these subjects was 19 Caucasians, 15 Asian Indians, and
1 Hispanic. In these subjects, urinary pH, ammonium, and
citrate all increased during hyperinsulinemia when com-
pared to baseline.
DISCUSSION
There are three salient findings in this study. First, in-
sulin resistance is associated with excessively low urinary
pH, which can potentially predispose the subjects to uric
acid stone formation. Second, obesity-related insulin re-
sistance significantly contributes to, but does not entirely
explain, the undue urinary acidity of uric acid nephrolithi-
asis patients. Third, insulin acutely affects renal acidifica-
tion in non-stone formers.
We deliberately chose overtly healthy subjects with
a wide degree of adiposity to ensure adequate spread
in insulin sensitivity measured using hyperinsulinemic-
euglycemic clamps. In this population of non-stone
formers, we found that decreased glucose disposal rate
correlated (Fig. 1) with reduction in mean 24-hour uri-
nary pH. The patients carrying a diagnosis of uric acid
nephrolithiasis were more obese and, likely as a conse-
quence, had more significant insulin resistance. It is note-
worthy that these patients were selected solely based on
the presence of uric acid kidney stones and not other
metabolic parameters, and yet they exhibited the least
sensitivity to insulin and the lowest urinary pH (Tables 2
and 3, Fig. 1).
We and others have previously shown that despite nor-
mouricosuria, patients with undue low urinary pH are
at increased risk for development of either uric acid or
mixed calcium oxalate/uric acid kidney stones. These pa-
tients typically have persistently low urinary pH (below
5.5), seemingly as a consequence of impaired ammonium
excretion when challenged with an acute acid load [4]. As
expected, low urinary pH was found in the uric acid stone
formers compared to the non-stone formers. Despite the
lower percentage of net acid excreted as ammonium, net
acid excretion was maintained by higher titratable acidity
and lower citrate. An as of yet unexplained finding is the
higher net acid excretion in uric acid stone formers de-
spite being on an identical diet as the non stone-formers.
Acid intake as indicated by sulfate excretion was simi-
lar in the two groups, with a numerically but statistically
insignificantly lower value in the uric acid stone-formers.
There may be a yet unrecognized increased intestinal base
loss in uric acid stone formers.
The mechanistic relationship between insulin resis-
tance and low urinary pH is unclear at the moment but it
may be secondary to defective ammonia synthesis both
by the proximal tubule cell as well as ammonium trans-
port into the renal tubular lumen. In vitro studies have
indicated that insulin stimulates renal ammoniagenesis
from the substrate L-glutamine [21, 22] and the proximal
renal tubule Na+/H+ exchanger [20] that is critical for
either direct transport or ionic trapping of NH+4 in the
urinary lumen [25]. Substrate competition may also play
a role. L-glutamine is both a major ammoniagenic and
ATP precursor for the renal proximal tubular cells. If an
alternative metabolic substrate, such as free fatty acids,
is provided to the proximal renal tubular cell, the result
is a reduction in glutamine usage and ammoniagenesis
[25–30]. It is of interest that insulin resistance is often as-
sociated with excessive plasma free fatty acid circulation
[31].
Clearly, the uric acid–stone formers had more insulin
resistance and lower urinary pH compared to the non-
stone formers. In addition, they tended to exhibit exces-
sively low urinary pH even for their degree of insulin
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resistance (Fig. 1). When we selected two subgroups of
similar age and body fat content (Table 4) we found exces-
sively low urinary pH in the stone formers independent of
insulin resistance and obesity. These results suggest that
uric acid–stone formers may have yet unidentified mech-
anisms leading to unduly low urinary pH that are not
entirely accounted for by insulin resistance. The mecha-
nism for the hypocitraturia is also unknown but may be
related to proximal tubular cell acidification due to de-
fective apical membrane H+ and NH+4 secretion. Alter-
natively, excessive proximal tubule luminal acidification
can increase apical membrane citrate uptake as long as
citrate metabolism is maintained high, and hypocitraturia
can ensue. The hypocitraturia may predispose uric acid
stone formers to have mixed uric acid/calcium stones.
Of interest are the findings on the effects of acute
hyperinsulinemia on urinary variables during the
hyperinsulinemic-euglycemic clamps. Acute renal effects
of insulin have included suppression of renal glucose re-
lease and stimulation of glucose uptake [32–34], alter-
ations in filtration rate [35–38], and natriuresis [15–17].
We now show that acute hyperinsulinemia induces eleva-
tion in urinary pH in the non-stone formers. This alkalin-
ization was accompanied by elevation of urinary citrate
and ammonia excretion. Our findings suggest that insulin
directly affects renal ammonium excretion in humans. It
is conceivable that reduced biologic activity of insulin in
the kidney may prevent elevation of urinary pH during
physiologic hyperinsulinemia, such as in post-absorptive
conditions. This altered kidney response to insulin may
determine a tendency toward a decrease in 24-hour mean
urinary pH in insulin resistant subjects.
CONCLUSION
This study shows that a possible renal manifestation
of insulin resistance is low urinary ammonium and pH.
Acid-base balance is maintained by increased titratable
acid and reduced citrate excretion. This defect is particu-
larly prevalent and pronounced in patients with uric acid
nephrolithiasis and results in increased risk of uric acid
precipitation despite hypouricosuria. In addition to the
reduced ammonium excretion associated with insulin re-
sistance, there are additional mechanisms leading to the
reduced ammonium excretion in uric acid stone form-
ers. Because a growing percentage of our population has
features of insulin resistance, as indicated by recent epi-
demiologic observations on the prevalence of obesity [1],
diabetes [39, 40], and the metabolic syndrome [2], there
may be a surge in the population risk and incidence for
kidney stones. Our study identifies insulin resistance as
a predisposing factor and major potential target of inter-
vention to either reduce risk for kidney stone formation
in high-risk patients or improve the clinical outcome of
patients who already have kidney stones.
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